Browse

Effect of the combination of mitiglinide and metformin on glycemic control in patients with type 2 diabetes mellitus

Cited 3 time in Web of Science Cited 4 time in Scopus
Authors
Cho, Young Min; Koo, Bo Kyung; Son, Ho Young; Lee, Kwang Woo; Choi, Dong Seop; Kim, Yong Ki; Lee, Hyun Chul; Chung, Min Young; Kim, Youngkun; Lee, Hong Kyu; Park, Kyong Soo; Yoo, Hyung Joon; Baek, Hong Sun; Min, Kyung Wan; Lee, Moon Kyu; Kim, Bo Wan; Son, Hyun Shik
Issue Date
2010-08
Publisher
WILEY-BLACKWELL
Citation
JOURNAL OF DIABETES INVESTIGATION; Vol.1 4; 143-148
Keywords
MitiglinideMetforminType 2 diabetes
Abstract
Aims/Introduction: Mitiglinide is the newest drug in the meglitinide family. It increases the early-phase insulin release through rapid association-dissociation kinetics in the pancreatic beta cells. The efficacy and safety of adding meglitinide to metformin monotherapy in patients with type 2 diabetes are unknown. Materials and Methods: We carried out a prospective, randomized, multicenter trial to assess the efficacy and safety of combined treatment with mitiglinide and metformin for patients with type 2 diabetes who showed inadequate glycemic control with metformin monotherapy. Subjects with glycated hemoglobin (HbA(1c)) > 7.0% after an 8-week metformin run-in phase were randomized to a 16-week trial phase with metformin plus mitiglinide (Met + Mit) or metformin plus placebo (Met + Pcb). Results: Compared with the Met + Pcb group, the Met + Mit group showed a greater reduction in HbA(1c) (-0.7 +/- 0.6% vs -0.4 +/- 0.7%, P = 0.002), fasting plasma glucose (-0.77 +/- 1.76 mmol/L vs -0.05 +/- 1.60 mmol/L, P = 0.015) and 2-h postprandial glucose (-3.76 +/- 3.57 mmol/L vs -0.84 +/- 3.07 mmol/L, P < 0.0001). The proportion of the patients who achieved the target HbA(1c) value of < 7% at the end of the study was also higher in the Met + Mit group than the Met + Pcb group (49.3% vs 28.8%, P = 0.016). There were no differences in the adverse event rates between groups. Conclusions: Combination therapy with metformin and mitiglinide is effective and safe for the treatment of patients with type 2 diabetes who have inadequate glycemic control with metformin monotherapy. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00023.x, 2010)
ISSN
2040-1116
Language
English
URI
http://hdl.handle.net/10371/77461
DOI
https://doi.org/10.1111/j.2040-1124.2010.00023.x
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse